Phenotypic screening in the 21st century

Frontiers in Pharmacology

Volumn 5, Issue NOV, 2014, Pages

  Priest, Birgit T ^a   Erdemli, Gul ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DIURETIC AGENT; VASODILATOR AGENT;

CELL ASSAY; CELL PROLIFERATION; DRUG DEVELOPMENT; DRUG TARGETING; EDITORIAL; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; IN VIVO STUDY; INSULIN RELEASE; MOLECULAR CLONING; NONHUMAN; PANCREAS ISLET BETA CELL; PHENOTYPE; PLURIPOTENT STEM CELL; THROMBOCYTE AGGREGATION;

EID: 84910619959     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00264     Document Type: Editorial

References (3)

1. Swinney DC. Phenotypic vs. target-based drug discovery for first-in-class medicines. Clinical pharmacology and therapeutics, 93(4), 299-301 (2013).
2. Landmark CJ, Johannessen SI. Modifications of antiepileptic drugs for improved tolerability and efficacy. Perspectives in medicinal chemistry, 2, 21-39 (2008).
3. Wu X, Zhang J, Zhen R et al. Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models. Journal of translational medicine, 10, 180 (2012)